|
1
|
Guidelines for the use and interpretation of assays for monitoring autophagy.
|
Autophagy
|
2012
|
20.08
|
|
2
|
Clinical effect of point mutations in myelodysplastic syndromes.
|
N Engl J Med
|
2011
|
9.90
|
|
3
|
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
|
Blood
|
2006
|
8.38
|
|
4
|
Revised international prognostic scoring system for myelodysplastic syndromes.
|
Blood
|
2012
|
8.12
|
|
5
|
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
|
Blood
|
2009
|
5.72
|
|
6
|
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.
|
Blood
|
2010
|
4.51
|
|
7
|
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.
|
Cancer Cell
|
2012
|
4.41
|
|
8
|
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
|
Blood
|
2003
|
4.07
|
|
9
|
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
|
J Clin Oncol
|
2005
|
4.06
|
|
10
|
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.
|
Cancer
|
2006
|
4.04
|
|
11
|
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
|
Clin Cancer Res
|
2005
|
4.00
|
|
12
|
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.
|
J Clin Oncol
|
2012
|
3.88
|
|
13
|
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.
|
Cancer
|
2008
|
3.75
|
|
14
|
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.
|
Blood
|
2002
|
3.46
|
|
15
|
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.
|
Blood
|
2007
|
3.29
|
|
16
|
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
|
Blood
|
2007
|
3.27
|
|
17
|
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
|
Blood
|
2003
|
3.18
|
|
18
|
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.
|
Nat Genet
|
2009
|
3.10
|
|
19
|
Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.
|
J Clin Oncol
|
2012
|
2.92
|
|
20
|
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.
|
Blood
|
2007
|
2.91
|
|
21
|
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
|
Cancer
|
2006
|
2.77
|
|
22
|
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
|
Blood
|
2003
|
2.75
|
|
23
|
Loss of the tumor suppressor BAP1 causes myeloid transformation.
|
Science
|
2012
|
2.69
|
|
24
|
DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.
|
Cancer Res
|
2006
|
2.69
|
|
25
|
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.
|
J Clin Oncol
|
2010
|
2.58
|
|
26
|
CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer.
|
Genome Res
|
2013
|
2.57
|
|
27
|
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.
|
J Clin Oncol
|
2008
|
2.54
|
|
28
|
Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.
|
Cancer
|
2010
|
2.41
|
|
29
|
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
|
J Clin Oncol
|
2003
|
2.41
|
|
30
|
Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid.
|
Leuk Res
|
2005
|
2.37
|
|
31
|
Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
|
Blood
|
2006
|
2.36
|
|
32
|
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
|
Clin Cancer Res
|
2006
|
2.33
|
|
33
|
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
|
Blood
|
2008
|
2.31
|
|
34
|
Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy.
|
Am J Hematol
|
2014
|
2.26
|
|
35
|
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
|
Blood
|
2005
|
2.21
|
|
36
|
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.
|
Blood
|
2010
|
2.19
|
|
37
|
Cause of death in patients with lower-risk myelodysplastic syndrome.
|
Cancer
|
2010
|
2.17
|
|
38
|
Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia.
|
Cancer
|
2009
|
2.15
|
|
39
|
Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia.
|
Blood
|
2007
|
2.11
|
|
40
|
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.
|
Blood
|
2003
|
2.06
|
|
41
|
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
|
Blood
|
2004
|
2.03
|
|
42
|
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.
|
J Clin Oncol
|
2010
|
2.02
|
|
43
|
Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial.
|
J Clin Oncol
|
2009
|
2.02
|
|
44
|
Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system.
|
J Clin Oncol
|
2011
|
2.02
|
|
45
|
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.
|
Blood
|
2010
|
1.95
|
|
46
|
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.
|
J Clin Oncol
|
2005
|
1.93
|
|
47
|
Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
|
Blood
|
2007
|
1.92
|
|
48
|
Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis.
|
J Clin Oncol
|
2013
|
1.88
|
|
49
|
Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.
|
Cancer
|
2007
|
1.88
|
|
50
|
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.
|
Blood
|
2003
|
1.87
|
|
51
|
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.
|
Blood
|
2002
|
1.87
|
|
52
|
Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms.
|
J Clin Oncol
|
2012
|
1.87
|
|
53
|
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.
|
J Natl Compr Canc Netw
|
2011
|
1.85
|
|
54
|
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
|
Blood
|
2009
|
1.82
|
|
55
|
Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
|
Cancer
|
2008
|
1.80
|
|
56
|
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
|
Blood
|
2003
|
1.76
|
|
57
|
SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value.
|
Blood
|
2011
|
1.73
|
|
58
|
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.
|
Blood
|
2006
|
1.73
|
|
59
|
K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis.
|
Cell Res
|
2011
|
1.72
|
|
60
|
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
|
Blood
|
2013
|
1.70
|
|
61
|
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.
|
Blood
|
2012
|
1.69
|
|
62
|
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
|
Clin Cancer Res
|
2004
|
1.68
|
|
63
|
Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia.
|
Cancer
|
2004
|
1.66
|
|
64
|
Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia.
|
Blood
|
2003
|
1.65
|
|
65
|
Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy.
|
Cancer
|
2010
|
1.65
|
|
66
|
Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer.
|
Int J Cancer
|
2009
|
1.64
|
|
67
|
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
|
J Clin Oncol
|
2009
|
1.64
|
|
68
|
Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia.
|
Leuk Lymphoma
|
2014
|
1.59
|
|
69
|
A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine.
|
Leuk Lymphoma
|
2012
|
1.57
|
|
70
|
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
|
Blood
|
2003
|
1.57
|
|
71
|
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia.
|
Blood
|
2008
|
1.57
|
|
72
|
Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model.
|
J Clin Oncol
|
2011
|
1.55
|
|
73
|
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.
|
Lancet Oncol
|
2012
|
1.54
|
|
74
|
Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies.
|
Cancer
|
2008
|
1.52
|
|
75
|
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
|
Blood
|
2008
|
1.52
|
|
76
|
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.
|
J Clin Oncol
|
2002
|
1.52
|
|
77
|
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.
|
Blood
|
2008
|
1.51
|
|
78
|
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.
|
Cancer
|
2003
|
1.50
|
|
79
|
Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy.
|
Blood
|
2010
|
1.50
|
|
80
|
Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia.
|
Blood
|
2006
|
1.49
|
|
81
|
Phase I study of bortezomib in refractory or relapsed acute leukemias.
|
Clin Cancer Res
|
2004
|
1.49
|
|
82
|
RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis.
|
Cancer Res
|
2007
|
1.48
|
|
83
|
Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission.
|
Biol Blood Marrow Transplant
|
2012
|
1.46
|
|
84
|
The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.
|
Blood
|
2011
|
1.46
|
|
85
|
Multi-color CD34⁺ progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia.
|
Leuk Res
|
2012
|
1.44
|
|
86
|
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.
|
Blood
|
2008
|
1.44
|
|
87
|
Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
|
Cancer
|
2007
|
1.44
|
|
88
|
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
|
Leuk Lymphoma
|
2007
|
1.42
|
|
89
|
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
|
Cancer
|
2003
|
1.42
|
|
90
|
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
|
Clin Cancer Res
|
2002
|
1.42
|
|
91
|
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.
|
Blood
|
2004
|
1.41
|
|
92
|
Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers.
|
Clin Cancer Res
|
2008
|
1.41
|
|
93
|
Outcome of adults with acute lymphocytic leukemia after second salvage therapy.
|
Cancer
|
2008
|
1.40
|
|
94
|
Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor.
|
Leuk Lymphoma
|
2014
|
1.40
|
|
95
|
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
|
Blood
|
2012
|
1.39
|
|
96
|
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.
|
Clin Cancer Res
|
2008
|
1.39
|
|
97
|
Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact.
|
Epigenetics
|
2010
|
1.37
|
|
98
|
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
|
Cancer
|
2007
|
1.37
|
|
99
|
Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia.
|
Leuk Res
|
2009
|
1.37
|
|
100
|
Biphenotypic acute leukaemia: a case series.
|
Br J Haematol
|
2007
|
1.36
|
|
101
|
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
|
J Clin Oncol
|
2008
|
1.34
|
|
102
|
Effect of cytarabine and decitabine in combination in human leukemic cell lines.
|
Clin Cancer Res
|
2007
|
1.33
|
|
103
|
Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
|
Cancer
|
2012
|
1.31
|
|
104
|
Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities.
|
Cancer
|
2009
|
1.29
|
|
105
|
Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.
|
J Clin Oncol
|
2004
|
1.28
|
|
106
|
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.
|
Blood
|
2004
|
1.28
|
|
107
|
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment.
|
J Clin Oncol
|
2009
|
1.27
|
|
108
|
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase.
|
Cancer
|
2009
|
1.27
|
|
109
|
Point-of-care biosensor systems for cancer diagnostics/prognostics.
|
Biosens Bioelectron
|
2006
|
1.26
|
|
110
|
Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
|
J Clin Oncol
|
2011
|
1.26
|
|
111
|
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
|
Blood
|
2002
|
1.25
|
|
112
|
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.
|
Blood
|
2008
|
1.25
|
|
113
|
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses.
|
Blood
|
2002
|
1.24
|
|
114
|
Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?
|
J Clin Oncol
|
2011
|
1.24
|
|
115
|
Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor.
|
Blood
|
2006
|
1.22
|
|
116
|
Therapy with azanucleosides for myelodysplastic syndromes.
|
Nat Rev Clin Oncol
|
2010
|
1.21
|
|
117
|
Thalidomide therapy for myelofibrosis with myeloid metaplasia.
|
Cancer
|
2006
|
1.18
|
|
118
|
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.
|
Cancer
|
2008
|
1.18
|
|
119
|
Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome.
|
J Clin Oncol
|
2009
|
1.17
|
|
120
|
Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse.
|
Leuk Res
|
2009
|
1.16
|
|
121
|
Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.
|
Cancer
|
2007
|
1.16
|
|
122
|
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.
|
Blood
|
2002
|
1.16
|
|
123
|
Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia.
|
Blood
|
2010
|
1.14
|
|
124
|
Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome.
|
Br J Haematol
|
2004
|
1.14
|
|
125
|
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.
|
Leuk Res
|
2003
|
1.13
|
|
126
|
Myelodysplastic syndromes: clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2013
|
1.12
|
|
127
|
Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate.
|
Blood
|
2010
|
1.12
|
|
128
|
Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia.
|
J Clin Oncol
|
2011
|
1.12
|
|
129
|
Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers.
|
Cancer Res
|
2004
|
1.11
|
|
130
|
Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers.
|
Blood
|
2011
|
1.10
|
|
131
|
Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome.
|
Blood
|
2011
|
1.09
|
|
132
|
Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy.
|
Blood
|
2010
|
1.09
|
|
133
|
Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration.
|
Cancer
|
2010
|
1.09
|
|
134
|
EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience.
|
Blood
|
2012
|
1.08
|
|
135
|
Decitabine in the treatment of myelodysplastic syndromes.
|
Expert Rev Anticancer Ther
|
2010
|
1.08
|
|
136
|
The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy.
|
Clin Cancer Res
|
2010
|
1.08
|
|
137
|
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia.
|
Clin Cancer Res
|
2004
|
1.08
|
|
138
|
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
|
Cancer
|
2014
|
1.08
|
|
139
|
Notch pathway activation induces neuroblastoma tumor cell growth arrest.
|
Pediatr Blood Cancer
|
2011
|
1.07
|
|
140
|
Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.
|
Cancer
|
2010
|
1.07
|
|
141
|
A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.
|
Cancer
|
2011
|
1.06
|
|
142
|
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
|
Cancer
|
2003
|
1.06
|
|
143
|
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
|
Cancer
|
2003
|
1.06
|
|
144
|
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
|
Blood
|
2005
|
1.06
|
|
145
|
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors.
|
Am J Hematol
|
2013
|
1.06
|
|
146
|
Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor.
|
Cancer
|
2010
|
1.05
|
|
147
|
Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
|
Cancer
|
2003
|
1.04
|
|
148
|
Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.
|
J Clin Oncol
|
2010
|
1.04
|
|
149
|
Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53.
|
Cancer
|
2011
|
1.03
|
|
150
|
Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
|
Cancer
|
2007
|
1.03
|
|
151
|
Potential cure of acute myeloid leukemia : analysis of 1069 consecutive patients in first complete remission.
|
Cancer
|
2007
|
1.02
|
|
152
|
Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin.
|
Cancer
|
2011
|
1.02
|
|
153
|
Outcome of patients with acute myelogenous leukemia after second salvage therapy.
|
Cancer
|
2005
|
1.01
|
|
154
|
Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia.
|
Cancer
|
2006
|
1.01
|
|
155
|
Activity of alemtuzumab in patients with CD52-positive acute leukemia.
|
Cancer
|
2006
|
1.01
|
|
156
|
Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia.
|
J Hematop
|
2008
|
1.01
|
|
157
|
Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor.
|
Expert Opin Investig Drugs
|
2011
|
1.00
|
|
158
|
HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target.
|
Mod Pathol
|
2006
|
1.00
|
|
159
|
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
|
Cancer
|
2010
|
1.00
|
|
160
|
Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status.
|
Leuk Res
|
2008
|
1.00
|
|
161
|
Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia.
|
J Clin Oncol
|
2008
|
1.00
|
|
162
|
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
|
Leuk Res
|
2006
|
1.00
|
|
163
|
Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate.
|
Blood
|
2005
|
0.99
|
|
164
|
Is acute myeloid leukemia a liquid tumor?
|
Int J Cancer
|
2013
|
0.99
|
|
165
|
The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.99
|
|
166
|
Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.
|
Cancer
|
2009
|
0.99
|
|
167
|
Comment on "Chromosomal instability and tumors promoted by DNA hypomethylation" and "Induction of tumors in nice by genomic hypomethylation".
|
Science
|
2003
|
0.99
|
|
168
|
Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
|
Cancer
|
2014
|
0.98
|
|
169
|
Philadelphia chromosome-positive acute lymphoblastic leukemia- current concepts and future perspectives.
|
Rev Clin Exp Hematol
|
2002
|
0.98
|
|
170
|
Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis.
|
Cancer
|
2009
|
0.98
|
|
171
|
Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course.
|
Cancer
|
2002
|
0.98
|
|
172
|
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
|
Cancer
|
2003
|
0.98
|
|
173
|
Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone.
|
Cancer
|
2006
|
0.97
|
|
174
|
Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation.
|
J Clin Oncol
|
2011
|
0.97
|
|
175
|
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
|
Clin Cancer Res
|
2002
|
0.97
|
|
176
|
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.
|
Am J Hematol
|
2013
|
0.96
|
|
177
|
A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia.
|
Br J Haematol
|
2010
|
0.96
|
|
178
|
Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia.
|
Am J Hematol
|
2013
|
0.96
|
|
179
|
Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy.
|
Cancer
|
2010
|
0.96
|
|
180
|
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.
|
Cancer
|
2008
|
0.95
|
|
181
|
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.
|
Am J Hematol
|
2015
|
0.95
|
|
182
|
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens.
|
Cancer
|
2006
|
0.94
|
|
183
|
DNA methylation in haematological malignancies: the role of decitabine.
|
Expert Opin Investig Drugs
|
2003
|
0.94
|
|
184
|
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience.
|
Cancer
|
2005
|
0.94
|
|
185
|
Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).
|
Cancer
|
2014
|
0.94
|
|
186
|
FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia.
|
Am J Hematol
|
2012
|
0.93
|
|
187
|
Improving survival in myelodysplastic syndromes.
|
Lancet Oncol
|
2009
|
0.93
|
|
188
|
Protein expression of a triad of frequently methylated genes, p73, p57Kip2, and p15, has prognostic value in adult acute lymphocytic leukemia independently of its methylation status.
|
J Clin Oncol
|
2005
|
0.93
|
|
189
|
Epigenetic therapy of leukemia: An update.
|
Int J Biochem Cell Biol
|
2008
|
0.92
|
|
190
|
Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.
|
Clin Cancer Res
|
2004
|
0.92
|
|
191
|
PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study.
|
Cancer
|
2007
|
0.92
|
|
192
|
Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia.
|
Leuk Res
|
2008
|
0.91
|
|
193
|
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.
|
Cancer
|
2004
|
0.91
|
|
194
|
A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias.
|
Cancer
|
2011
|
0.91
|
|
195
|
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies.
|
Clin Cancer Res
|
2005
|
0.91
|
|
196
|
Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy.
|
Cancer
|
2006
|
0.91
|
|
197
|
Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD.
|
Br J Haematol
|
2013
|
0.91
|
|
198
|
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.
|
Clin Cancer Res
|
2005
|
0.90
|
|
199
|
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
|
Cancer
|
2003
|
0.90
|
|
200
|
Lack of p21(CIP1) DNA methylation in acute lymphocytic leukemia.
|
Blood
|
2002
|
0.90
|
|
201
|
Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal.
|
Cancer
|
2006
|
0.90
|
|
202
|
Epigenetic inactivation of Notch-Hes pathway in human B-cell acute lymphoblastic leukemia.
|
PLoS One
|
2013
|
0.89
|
|
203
|
Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.
|
Cancer
|
2009
|
0.89
|
|
204
|
Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents.
|
Leuk Lymphoma
|
2014
|
0.89
|
|
205
|
Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes.
|
Am J Hematol
|
2014
|
0.89
|
|
206
|
Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome.
|
Br J Haematol
|
2007
|
0.88
|
|
207
|
Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies.
|
Haematologica
|
2012
|
0.88
|
|
208
|
Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome.
|
BMC Med Genet
|
2010
|
0.88
|
|
209
|
Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.88
|
|
210
|
Evolving strategies in the treatment of MDS and AML.
|
Clin Adv Hematol Oncol
|
2009
|
0.88
|
|
211
|
Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
|
Cancer
|
2003
|
0.87
|
|
212
|
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
|
Cancer
|
2002
|
0.87
|
|
213
|
Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes.
|
Cancer
|
2014
|
0.87
|
|
214
|
Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.
|
Br J Haematol
|
2010
|
0.87
|
|
215
|
EphB2 activity plays a pivotal role in pediatric medulloblastoma cell adhesion and invasion.
|
Neuro Oncol
|
2012
|
0.87
|
|
216
|
Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS.
|
Cancer
|
2012
|
0.87
|
|
217
|
Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience.
|
Am J Hematol
|
2004
|
0.87
|
|
218
|
Epigenetic therapy in allogeneic hematopoietic stem cell transplantation.
|
Rev Bras Hematol Hemoter
|
2013
|
0.87
|
|
219
|
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
|
Leuk Res
|
2005
|
0.86
|
|
220
|
Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies.
|
Leuk Res
|
2004
|
0.86
|
|
221
|
Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
|
Cancer
|
2003
|
0.86
|
|
222
|
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
|
Cancer
|
2003
|
0.86
|
|
223
|
Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells.
|
J Cell Mol Med
|
2009
|
0.86
|
|
224
|
Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody.
|
Am J Hematol
|
2015
|
0.86
|
|
225
|
The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy.
|
Autophagy
|
2010
|
0.86
|
|
226
|
2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome.
|
Cancer
|
2005
|
0.86
|
|
227
|
Aberrant DNA methylation of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia.
|
Leuk Res
|
2005
|
0.85
|
|
228
|
Current and future management options for myelodysplastic syndromes.
|
Drugs
|
2010
|
0.85
|
|
229
|
Safety and efficacy of azacitidine in myelodysplastic syndromes.
|
Drug Des Devel Ther
|
2010
|
0.85
|
|
230
|
Overexpression of the toll-like receptor (TLR) signaling adaptor MYD88, but lack of genetic mutation, in myelodysplastic syndromes.
|
PLoS One
|
2013
|
0.85
|
|
231
|
Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study.
|
Cancer
|
2010
|
0.85
|
|
232
|
Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor.
|
Leuk Res
|
2009
|
0.85
|
|
233
|
Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.
|
Cancer Chemother Pharmacol
|
2014
|
0.85
|
|
234
|
MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy.
|
Elife
|
2013
|
0.85
|
|
235
|
Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib.
|
Cancer
|
2011
|
0.85
|
|
236
|
Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.
|
Am J Hematol
|
2013
|
0.85
|
|
237
|
Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA.
|
Am J Hematol
|
2011
|
0.84
|
|
238
|
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
|
Blood
|
2009
|
0.84
|
|
239
|
RIZ1 is potential CML tumor suppressor that is down-regulated during disease progression.
|
J Hematol Oncol
|
2009
|
0.84
|
|
240
|
Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia.
|
Cancer Chemother Pharmacol
|
2002
|
0.84
|
|
241
|
RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype.
|
Br J Haematol
|
2015
|
0.83
|
|
242
|
Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome.
|
Br J Haematol
|
2012
|
0.83
|
|
243
|
Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study.
|
Clin Lymphoma Myeloma Leuk
|
2012
|
0.83
|
|
244
|
Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.
|
J Clin Oncol
|
2005
|
0.83
|
|
245
|
The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.83
|
|
246
|
Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission.
|
Leuk Lymphoma
|
2010
|
0.83
|
|
247
|
Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy.
|
Cancer
|
2012
|
0.83
|
|
248
|
Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies.
|
Leuk Res
|
2013
|
0.83
|
|
249
|
Acute myeloid leukemia outcome: role of nucleotide excision repair polymorphisms in intermediate risk patients.
|
Leuk Lymphoma
|
2010
|
0.83
|
|
250
|
The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?
|
Cancer
|
2009
|
0.83
|
|
251
|
Acute myeloid leukemia with t(9;11)(p21-22;q23): common properties of dysregulated ras pathway signaling and genomic progression characterize de novo and therapy-related cases.
|
Am J Clin Pathol
|
2010
|
0.83
|
|
252
|
The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes.
|
Ann Hematol
|
2013
|
0.83
|
|
253
|
De novo acute myeloid leukemia risk factors: a Texas case-control study.
|
Cancer
|
2012
|
0.83
|
|
254
|
Myelodysplastic syndromes.
|
J Natl Compr Canc Netw
|
2008
|
0.83
|
|
255
|
Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse.
|
Leuk Lymphoma
|
2013
|
0.83
|
|
256
|
Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.83
|
|
257
|
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2017
|
0.83
|
|
258
|
Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.82
|
|
259
|
Treatment strategies in myelodysplastic syndromes.
|
Cancer Invest
|
2008
|
0.82
|
|
260
|
Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia.
|
Leuk Res
|
2005
|
0.82
|
|
261
|
Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience.
|
Leuk Lymphoma
|
2013
|
0.82
|
|
262
|
Relapse and death during first remission in acute myeloid leukemia.
|
Haematologica
|
2008
|
0.82
|
|
263
|
Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse.
|
Br J Haematol
|
2006
|
0.82
|
|
264
|
Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia.
|
Blood
|
2013
|
0.82
|
|
265
|
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS).
|
J Hematol Oncol
|
2012
|
0.82
|
|
266
|
Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.
|
Clin Lymphoma Myeloma Leuk
|
2012
|
0.82
|
|
267
|
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
|
Cancer
|
2003
|
0.82
|
|
268
|
Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy.
|
Cancer
|
2004
|
0.81
|
|
269
|
Pharmacokinetic evaluation of decitabine for the treatment of leukemia.
|
Expert Opin Drug Metab Toxicol
|
2011
|
0.81
|
|
270
|
Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy.
|
Oncologist
|
2009
|
0.81
|
|
271
|
Dietary intake of vegetables, fruits, and meats/beans as potential risk factors of acute myeloid leukemia: a Texas case-control study.
|
Nutr Cancer
|
2013
|
0.81
|
|
272
|
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
|
Leuk Res
|
2003
|
0.81
|
|
273
|
Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy.
|
Clin Adv Hematol Oncol
|
2008
|
0.81
|
|
274
|
Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.
|
Cancer
|
2014
|
0.81
|
|
275
|
Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia.
|
J Hematol Oncol
|
2014
|
0.80
|
|
276
|
Feasibility of therapy with hypomethylating agents in patients with renal insufficiency.
|
Clin Lymphoma Myeloma Leuk
|
2010
|
0.80
|
|
277
|
Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome.
|
Am J Hematol
|
2011
|
0.80
|
|
278
|
C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome.
|
Leuk Res
|
2004
|
0.80
|
|
279
|
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.
|
Cancer
|
2007
|
0.80
|
|
280
|
Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution.
|
Am J Hematol
|
2014
|
0.80
|
|
281
|
Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias.
|
Genes Chromosomes Cancer
|
2010
|
0.80
|
|
282
|
Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience.
|
Am J Hematol
|
2014
|
0.80
|
|
283
|
Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.80
|
|
284
|
Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.
|
Am J Hematol
|
2014
|
0.80
|
|
285
|
Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide.
|
Leuk Lymphoma
|
2014
|
0.80
|
|
286
|
BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS.
|
Am J Hematol
|
2014
|
0.79
|
|
287
|
The role of decitabine in the treatment of myelodysplastic syndromes.
|
Expert Opin Pharmacother
|
2007
|
0.79
|
|
288
|
Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system.
|
Cancer
|
2012
|
0.79
|
|
289
|
Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications.
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.79
|
|
290
|
Standard therapy for patients with myelodysplastic syndromes.
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.79
|
|
291
|
Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.
|
Am J Hematol
|
2014
|
0.79
|
|
292
|
Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia.
|
Am J Hematol
|
2014
|
0.79
|
|
293
|
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
|
J Clin Oncol
|
2003
|
0.79
|
|
294
|
Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia.
|
Br J Haematol
|
2014
|
0.79
|
|
295
|
Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis.
|
Br J Haematol
|
2014
|
0.79
|
|
296
|
Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia.
|
Blood
|
2008
|
0.78
|
|
297
|
T-cell prolymphocytic leukemia: a single-institution experience.
|
Clin Lymphoma Myeloma
|
2005
|
0.78
|
|
298
|
Characteristics of pericardial effusions in patients with leukemia.
|
Cancer
|
2010
|
0.78
|
|
299
|
Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia.
|
Br J Haematol
|
2014
|
0.78
|
|
300
|
Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy.
|
Leuk Lymphoma
|
2010
|
0.78
|
|
301
|
Histone methylation in myelodysplastic syndromes.
|
Epigenomics
|
2011
|
0.77
|
|
302
|
Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986.
|
Cancer
|
2005
|
0.77
|
|
303
|
The search for better prognostic models in myelodysplastic syndromes.
|
Curr Hematol Malig Rep
|
2011
|
0.77
|
|
304
|
Prediction model for mortality after intracranial hemorrhage in patients with leukemia.
|
Am J Hematol
|
2011
|
0.77
|
|
305
|
Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy.
|
Haematologica
|
2002
|
0.77
|
|
306
|
Deacetylase inhibitors for the treatment of myelodysplastic syndromes.
|
Leuk Lymphoma
|
2015
|
0.77
|
|
307
|
Myelodysplastic syndromes with deletions of chromosome 11q lack cryptic MLL rearrangement and exhibit characteristic clinicopathologic features.
|
Leuk Res
|
2010
|
0.77
|
|
308
|
Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study.
|
Am J Hematol
|
2013
|
0.77
|
|
309
|
Low frequency of H3.3 mutations and upregulated DAXX expression in MDS.
|
Blood
|
2013
|
0.77
|
|
310
|
Evaluation of epidemiological factors in survival of patients with de novo myelodysplastic syndromes.
|
Cancer Causes Control
|
2014
|
0.77
|
|
311
|
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
|
Clin Lymphoma Myeloma Leuk
|
2012
|
0.77
|
|
312
|
The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
|
Cancer
|
2008
|
0.76
|
|
313
|
Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations.
|
Leuk Lymphoma
|
2013
|
0.76
|
|
314
|
Clinical and cytogenetic characteristics of myelodysplastic syndrome in patients with HIV infection.
|
Leuk Res
|
2012
|
0.76
|
|
315
|
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia.
|
Cancer Chemother Pharmacol
|
2003
|
0.76
|
|
316
|
Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy.
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.76
|
|
317
|
Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.76
|
|
318
|
Use of hypomethylating agents in myelodysplastic syndromes.
|
Clin Adv Hematol Oncol
|
2007
|
0.76
|
|
319
|
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
|
Cancer
|
2003
|
0.76
|
|
320
|
Management of myelodysplastic syndromes: just the beginning.
|
Oncology (Williston Park)
|
2008
|
0.76
|
|
321
|
Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature.
|
Leuk Res
|
2004
|
0.75
|
|
322
|
Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.
|
Clin Lymphoma Myeloma Leuk
|
2012
|
0.75
|
|
323
|
Role of epigenetic therapy in myelodysplastic syndrome.
|
Expert Rev Hematol
|
2008
|
0.75
|
|
324
|
Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.75
|
|
325
|
The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes.
|
Leuk Lymphoma
|
2014
|
0.75
|
|
326
|
Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
|
Clin Cancer Res
|
2002
|
0.75
|
|
327
|
Therapy for older patients with acute myeloblastic leukemia: a problem in search of a solution.
|
Leuk Lymphoma
|
2012
|
0.75
|
|
328
|
Myelodysplastic syndromes should been renamed as myelodysplastic neoplasms.
|
Leuk Res
|
2013
|
0.75
|
|
329
|
Interaction between myelomonocytic and lymphoid cells in a patient with acute myelomonocytic leukemia and chronic lymphocytic leukemia.
|
Leuk Lymphoma
|
2014
|
0.75
|
|
330
|
Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.75
|
|
331
|
Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).
|
Br J Haematol
|
2009
|
0.75
|
|
332
|
Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia.
|
Am J Hematol
|
2012
|
0.75
|
|
333
|
Rare case of septic arthritis caused by Candida krusei: case report and literature review.
|
J Rheumatol
|
2012
|
0.75
|
|
334
|
Current management of patients with chronic myelomonocytic leukemia.
|
Curr Opin Oncol
|
2017
|
0.75
|
|
335
|
Association of anemia and cognitive dysfunction in patients with acute myelogenous leukemia and myelodysplastic syndrome.
|
Am J Hematol
|
2011
|
0.75
|
|
336
|
Introduction: advances in myelodysplastic syndromes.
|
Semin Oncol
|
2011
|
0.75
|
|
337
|
Corrigendum: Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia.
|
Nat Immunol
|
2017
|
0.75
|
|
338
|
Infrequent presentations of mucormycosis in patients with myelodysplastic syndrome and acute leukemia: case series and review of literature.
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.75
|
|
339
|
New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia.
|
Appl Immunohistochem Mol Morphol
|
2017
|
0.75
|
|
340
|
Cytoprotection in acute myelogenous leukemia (AML) therapy.
|
Semin Oncol
|
2004
|
0.75
|
|
341
|
Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome.
|
Acta Haematol
|
2002
|
0.75
|
|
342
|
Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia.
|
Leuk Res
|
2003
|
0.75
|
|
343
|
Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML.
|
Leuk Res
|
2003
|
0.75
|